<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01256255</url>
  </required_header>
  <id_info>
    <org_study_id>UOA-FLU-2010-11</org_study_id>
    <nct_id>NCT01256255</nct_id>
  </id_info>
  <brief_title>Influenza Virus - A Multicenter Registry</brief_title>
  <official_title>INFLUENZA VIRUS INFECTIONS IN TRANSPLANT RECIPIENTS: A MULTICENTER REGISTRY</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alberta</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators purpose is to prospectively characterize influenza infections over a 3 year&#xD;
      period in transplant patients using a registry system. The investigators plan to generate&#xD;
      robust data on clinical features of upper and lower respiratory disease, antiviral therapy&#xD;
      and its effects on disease outcome, as well as quantitative virologic data on shedding and&#xD;
      antiviral resistance. The investigators also will study the long term sequelae of influenza&#xD;
      infections and look at development of rejection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be a prospective, multi-center study conducted at investigator sites who&#xD;
      comprise the Influenza in Transplant collaborative study group. This includes over 30 centers&#xD;
      from across North America and Europe. The co-ordinating center will be the University of&#xD;
      Alberta. We will aim to enrol 300 patients in the registry over a 3 year period.&#xD;
&#xD;
      The following information will be gathered:&#xD;
&#xD;
        1. Clinical Information&#xD;
&#xD;
             -  Baseline demographic information about the transplant (including immunosuppression,&#xD;
                graft function)&#xD;
&#xD;
             -  Comorbidities such as diabetes, obesity, chronic lung disease&#xD;
&#xD;
             -  Symptoms of infection, radiologic features of infections&#xD;
&#xD;
             -  Antiviral use&#xD;
&#xD;
             -  History of vaccination&#xD;
&#xD;
             -  Outcomes such as hospitalization, ICU admission, mechanical ventilation, death&#xD;
&#xD;
             -  Long term outcomes: allograft function, chronic respiratory disease&#xD;
&#xD;
             -  Laboratory parameters including lymphocyte count, immunoglobulin levels, renal&#xD;
                function&#xD;
&#xD;
             -  Adverse events - all serious adverse events occurring during the study (till day&#xD;
                180) will be reported. These include: a) hospitalization; b) congenital deformity;&#xD;
                c) death; d) disability; and e) other adverse events the investigator considers&#xD;
                serious. Pregnancy during the follow-up period will also be reported.&#xD;
&#xD;
        2. Virology&#xD;
&#xD;
             -  Method of diagnosis (DFA, viral culture, PCR)&#xD;
&#xD;
             -  Subtype of influenza virus (ie HxNx)&#xD;
&#xD;
             -  Viral Shedding by serial NP swabs at day 0 (diagnosis), 3, 6, 11, 18, 28 (weekly&#xD;
                thereafter if shedding persists)&#xD;
&#xD;
             -  Quantitative PCR of NP swabs (centrally at University of Alberta)&#xD;
&#xD;
             -  Antiviral resistance testing at first and last positive swabs&#xD;
&#xD;
        3. Immunology - Serum collection at disease onset and 4-6 weeks afterwards for&#xD;
&#xD;
             -  Serology against circulating influenza viruses&#xD;
&#xD;
             -  Production of HLA alloantibodies&#xD;
&#xD;
      Significance:&#xD;
&#xD;
      Despite the recognized importance of influenza in transplant patients, there is actually very&#xD;
      limited prospective data. This registry will represent the largest prospective data&#xD;
      collection on influenza in transplant patients and will provide invaluable data on the&#xD;
      clinical presentations, antiviral efficacy and other parameters related to influenza.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>November 2010</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Influenza Infection in Transplant Patients</condition>
  <arm_group>
    <arm_group_label>influenza infection</arm_group_label>
    <description>Patients with the diagnosis of influenza infection by standard laboratory technique</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum and nasal swabs&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Solid organ transplant recipients on at least one immunosuppressive medication and&#xD;
        Hematopoietic stem cell transplant recipients (allogeneic or autologous) with the diagnosis&#xD;
        of influenza infection by standard laboratory technique&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Solid organ transplant recipients on at least one immunosuppressive medication&#xD;
&#xD;
          -  Hematopoietic stem cell transplant recipients - allogeneic or autologous&#xD;
&#xD;
          -  Pediatric or Adult&#xD;
&#xD;
          -  Diagnosis of influenza infection by standard laboratory technique&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        not able to comply with the protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deepali Kumar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alberta</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2E1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <study_first_submitted>December 6, 2010</study_first_submitted>
  <study_first_submitted_qc>December 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2010</study_first_posted>
  <last_update_submitted>May 26, 2015</last_update_submitted>
  <last_update_submitted_qc>May 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alberta</investigator_affiliation>
    <investigator_full_name>Deepali Kumar</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>transplant</keyword>
  <keyword>influenza infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

